Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15093737 | 0.83 | ESR2 (0.38) | ESR2CYP2C9ESR1 | |
| SCHEMBL8990466 | 0.82 | ESR2 (0.39) | PDE10AESR2IKBKETBK1TRPV3 | |
| SCHEMBL11904971 | 0.80 | ESR2 (0.47) | ESR2CYP2C9ESR1 | |
| SCHEMBL11905003 | 0.80 | ESR2 (0.47) | ESR2CYP2C9ESR1 | |
| SCHEMBL31072949 | 0.80 | HTR2C (0.43) | — | |
| SCHEMBL11904997 | 0.80 | ESR2 (0.47) | ESR2CYP2C9ESR1 | |
| SCHEMBL11920525 | 0.78 | ESR2 (0.47) | ESR2 | |
| SCHEMBL22873436 | 0.76 | PDE10A (0.34) | PDE10AESR2IKBKETBK1C5AR1 | |
| SCHEMBL14403053 | 0.76 | ESR2 (0.42) | ESR2IKBKETBK1TRPV3ESR1 | |
| SCHEMBL8451083 | 0.75 | SPHK1 (0.43) | C5AR1MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | PSEN1, PRNP, PSEN2 | PDE10A 1120/4885ESR2 3789/4885IKBKE 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.